The committee will discuss biologics license application (BLA) 761209, for retifanlimab injection, submitted by Incyte Corporation. The proposed indication (use) for this product is for the treatment of adult patients with locally advanced or metastatic squamous carcinoma of the anal canal (SCAC) who have progressed on or who are intolerant of platinum-based chemotherapy.
Back to All Events
Earlier Event: June 10
Vaccines and Related Biological Products Advisory Committee
Later Event: July 15
Cardiovascular and Renal Drugs Advisory Committee